scorecardresearch
Tuesday, July 29, 2025
TopicFavipiravir

Topic: favipiravir

Potential Covid drug favipiravir to be available at Rs 103/pill at pharmacies by month-end

A selection of the best news reports, analysis and opinions published by ThePrint this week.

Favipiravir, Japanese drug that’s the new Covid treatment hope your chemist will soon stock

Favipiravir, a drug approved for treating influenza in Japan & China, has shown promise in studies. But many researchers have urged caution in the interpretation of the results. 

Glenmark enrols 150 patients to test favipiravir, the ‘most sought-after drug for Covid’

The dosage frequency of the tablets will be 1,800 mg twice on first day, 800 mg twice on second day, which will then be followed for up to a maximum of 14 days.

India to test Japanese flu drug favipiravir on Covid patients, Glenmark first to start trials

Favipiravir is among the drugs under trial for Covid-19 treatment along with anti-malarial medicine hydroxychloroquine and the Ebola drug remdesivir. 

On Camera

No one should have to choose between a roof and two meals. But India’s migrants do, every day

India’s policymakers need to ensure that labourers, and milk and newspaper delivery workers, do not have to sacrifice food just to keep a roof over their heads.

Govt’s earlier FDI limit of 74% in insurance sector has remained underutilised, Parliament told

In the latest budget, the FDI limit was increased to 100 percent, but most foreign companies are not buying such large stakes in the Indian insurance sector.

How Op Mahadev unfolded: A day-by-day account of how the net closed in on Pahalgam terrorists

New Delhi: The killing of the three LeT terrorists behind the Pahalgam massacre was the culmination of an operation that started immediately after the...

Modi’s Bharat vs Indira’s India: 11-yr report card of politics, diplomacy, economy, nationalism

As Narendra Modi becomes India’s second-longest consecutively serving Prime Minister, we look at how he compares with Indira Gandhi across four key dimensions.